ADM Biopolis

ADM Biopolis is a leading biotechnology company specializing in the research, development, and production of probiotics and other microbial solutions for the food, pharmaceutical, and agricultural sectors. Originally founded as a spin-off from the Spanish National Research Council (CSIC), the company was acquired by Archer Daniels Midland (ADM) in 2017 to serve as a cornerstone of its health and wellness business. The company utilizes a unique high-throughput screening platform based on the model organism Caenorhabditis elegans to rapidly evaluate the functional efficacy of new microbial strains and bioactive compounds. Their portfolio includes clinically validated probiotic strains, such as BPL1, which target metabolic health, skin conditions, and gut microbiome balance. ADM Biopolis operates state-of-the-art facilities in Valencia, Spain, offering both proprietary health ingredients and contract manufacturing services for microbial fermentation. The company's approach integrates genomics, proteomics, and systems biology to provide science-based nutritional solutions.